Acinetobacter baumannii is undoubtedly one of the most successful pathogens responsible
for hospital-acquired nosocomial infections in the modern healthcare system. Due to the …

Acinetobacter baumannii (named in honor of the American bacteriologists Paul and Linda
Baumann) is a Gram-negative, multidrug-resistant (MDR) pathogen that causes nosocomial …

Antibiotic resistance is one of the biggest challenges for the clinical sector and industry,
environment and societal development. One of the most important pathogens responsible …

Colistin is the last resort for treatment of multidrug-resistant Acinetobacter baumannii.
Unfortunately, resistance to colistin has been reported all over the world. The highest …

Background: The superiority of combination therapy for carbapenem-resistant Gram-
negative bacilli (CR-GNB) remains controversial. In vitro models may predict the efficacy of …

Our objective was to examine the evidence of in vitro synergy of polymyxin-carbapenem
combination therapy against Gram-negative bacteria (GNB). A systematic review and meta …

We assessed the prevalence of polymyxin B (PMB)-and tigecycline (TGC)-heteroresistant
Klebsiella pneumoniae isolates and investigated the combined effect of PMB and TGC …

Antimicrobial combinations are at the moment the only potential treatment option for
pandrug-resistant A. baumannii. A systematic review was conducted in PubMed and Scopus …

Background Acinetobacter baumannii is a nosocomial pathogen that has emerged as a
major threat in the health-care settings, particularly intensive care units (ICUs). The aim of …

The increasing emergence of antibiotics resistance is of global concern. Finding novel
antimicrobial agents and strategies based on synergistic combinations are essential to …